You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Blasts

Showing 1 - 25 of 1,242
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 Trial in Boston (BXCL701)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome With Excess Blasts-2
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 26, 2023

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts Trial (Biospecimen

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Biospecimen Collection
  • +3 more
  • (no location specified)
Oct 27, 2022

MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

Recruiting
  • Myelodysplastic Syndromes
  • Myeloproliferative Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

Recruiting
  • BCR-JAK2 Fusion Protein Expression
  • +11 more
  • Palo Alto, California
  • +3 more
Oct 5, 2022

The Effects of Chronic Exposure to Low-Level Blasts

Completed
  • Tramatic Brain Injury
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 27, 2023

    Acute Myeloid Leukemia, Myelodysplasia Trial in United States (MGTA-117)

    Recruiting
    • Acute Myeloid Leukemia
    • Myelodysplasia
    • MGTA-117
    • Duarte, California
    • +7 more
    Nov 23, 2022

    Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,

    Not yet recruiting
    • Acute Myelogenous Leukemia
    • +17 more
    • Peripheral Blood Stem Cell Transplant
    • +7 more
    • Minneapolis, Minnesota
      Masonic Cancer Center at University of Minnesota
    Mar 27, 2023

    Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,

    Completed
    Has Results
    • Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 18, 2022

    Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage Trial in United States (radiation, drug,

    Recruiting
    • Acute Biphenotypic Leukemia
    • +11 more
    • Total-Body Irradiation
    • +8 more
    • Los Angeles, California
    • +9 more
    Aug 19, 2022

    Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,

    Active, not recruiting
    • Acute Myeloid Leukemia
    • +6 more
    • Baltimore, Maryland
    • +2 more
    Feb 25, 2022

    Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome Trial in United

    Completed
    • Chronic Myelomonocytic Leukemia
    • +4 more
    • Los Angeles, California
    • +4 more
    Oct 5, 2022

    Leukemia, MDS, Childhood Acute Myeloid Leukemia in Remission Trial in Minneapolis (biological, drug, procedure)

    Recruiting
    • Leukemia
    • +12 more
    • filgrastim
    • +6 more
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Jan 20, 2022

    Cancer, MDS-EB, MDS Trial in Athens, Southampton, Sheffield (INKmune)

    Recruiting
    • Cancer
    • +4 more
    • INKmune
    • Athens, Attiki, Greece
    • +2 more
    Jul 3, 2023

    MDS, Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts, Mixed Myelodysplastic/Myeloproliferative

    Recruiting
    • Myelodysplastic Syndromes
    • +2 more
    • Stockholm, Sweden
      Department of Hematology, Karolinska University Hospital
    Mar 27, 2023

    Acute Myeloid Leukemia, MDS Trial in Ulm (drug, combination product, other)

    Recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • Berlin, Germany
    • +9 more
    Jan 13, 2023

    Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of

    Active, not recruiting
    • Acute Myeloid Leukemia With Multilineage Dysplasia
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 25, 2022

    Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5

    Withdrawn
    • Allogeneic Hematopoietic Stem Cell Transplantation Recipient
    • +7 more
    • Inotuzumab Ozogamicin
    • +2 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Jan 13, 2022

    MDS, AML Trial in France (venetoclax + azacitidine +/- donor lymphocyte infusion)

    Not yet recruiting
    • MDS
    • AML
    • venetoclax + azacitidine +/- donor lymphocyte infusion
    • Amiens, France
    • +13 more
    Jul 21, 2022

    Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in

    Recruiting
    • Acute Biphenotypic Leukemia
    • +13 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 19, 2023

    Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in Seattle

    Recruiting
    • Acute Biphenotypic Leukemia
    • +5 more
    • Dilanubicel
    • +6 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    May 11, 2022

    Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid

    Recruiting
    • Acute Lymphoblastic Leukemia in Remission
    • +11 more
    • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 24, 2022

    Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia Trial in United States (drug, radiation,

    Recruiting
    • Acute Erythroid Leukemia
    • +10 more
    • San Francisco, California
    • +5 more
    Nov 1, 2022

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,

    Recruiting
    • Blasts 5 Percent or More of Bone Marrow Nucleated Cells
    • +4 more
    • ADCT-602
    • Monrovia, California
    • +1 more
    Dec 7, 2022

    Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +11 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 29, 2022

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia

    Completed
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +14 more
    • Aldesleukin
    • +7 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 31, 2022